Rapa-501 autologous t cells (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04220190 (ClinicalTrials.gov) | December 15, 2020 | 3/1/2020 | RAPA-501 Therapy for ALS | Phase I Trial of Autologous Hybrid TREG/Th2 Cell (RAPA-501) Therapy for Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: RAPA-501 Autologous T cells | Rapa Therapeutics LLC | Massachusetts General Hospital;Hackensack Meridian Health | Not yet recruiting | 18 Years | N/A | All | 18 | Phase 1;Phase 2 | United States |